Managing relapses during or after adjuvant CDK4/6 inhibitors in HR-positive/HER2-negative early breast cancer: an emerging challenge.

Auteurs

Gerosa R, Gentile G, Arecco L, Dauccia C, Nannini S, Lobo-Martins S, Agostinetto E, Lambertini M, Santoro A, Aftimos P, Piccart-Gebhart M, de Azambuja E

  • Date de publication

    September 2025

  • Type

    Article

  • Tijdschrift

    ESMO Open

  • Naam van de onderzoeker

    DE AZAMBUJA EVANDRO

  • Hôpital

    Institut Jules Bordet

  • Dienst

    Médecine Oncologique

  • PMID

    40913835

  • DOI

    10.1016/j.esmoop.2025.105758